Preclinical work led to study of mGluR5 NAMs in humans with FXS, initially through a phase 1b pharmacokinetic (PK)/pharmacodynamic PD single-dose study of fenobam showing normalization of prepulse inhibition deficits (20). Here, GRM5 is linked to fragile X syndrome.